Table 3 Application of CAFs-related markers in clinical solid cancer immunity (Data source: ClinicalTrials.gov: https://beta.clinicaltrials.gov/ provided by the U.S. National Library of Medicine.)
From: Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Target | Cancer type | Application phase | Purpose of application | Clinical Trial No |
|---|---|---|---|---|
FAP | Breast cancer | Not Applicable | 68Â Ga conjugated FAPI for targeted FAP and tumor-matrix imaging | NCT05574907 |
Diagnostic value of AL18F-fluorodeoxyglucose(18F-FDG)- NOTA-FAPI PET/CT in cancer | NCT05574920 | |||
Gastrointestinal cancers | Phase II | Assess efficacy of 18F-FAPI-74 to detect FAP expressing cells in patients | NCT05641896 | |
Malignant neoplasms | Not Applicable | The diagnostic value of 68Â Ga-FAPI PET/CT in malignant tumors, especially those with low FDG uptake | NCT05034146 | |
The diagnostic value of 18F-FAPI PET / CT in various cancers and to compare it with 18F-FDG PET / CT | NCT05485792 | |||
Advanced solid tumors | Phase I | Dose escalation study of OMTX7 as a single agent in combination with Pembrolizumab (PD-1 mAb) in patients with advanced solid tumors to assess safety and tolerability | NCT05547321 | |
Meflin | Pancreatic cancer | Phase I/II | To evaluate the safety and tolerability of Am80 in combination with gemcitabine (GEM) and nattaxol in patients with unresectable pancreatic cancer and to determine the recommended dose | NCT05064618 |
FGFR, PDGFR, VEGFR | Non-small cell lung cancer | Phase I/II | Efficacy and tolerability of Nintedanib in combination with PD-1 antibody and CTLA-4 antibody | NCT03377023 |
Advanced solid tumors | Phase Ib | Anti-angiogenic combined with anti-PD-1 therapy to explore the efficacy | NCT02856425 | |
MCT-4, caveolin-1 | Breast cancer | Phase I(completed) | To assess the feasibility of the effect of n-acetylcysteine on tumor cell metabolism | NCT01878695 |
/ | Pancreatic cancer | Not Applicable | Establishment of mixed organoid model to predict drug response | NCT05571956, NCT05196334 |